Navigation Links
IDM Pharma Appoints Gregory J. Tibbitts to Board of Directors
Date:4/4/2008

IRVINE, Calif., April 4, 2008 /PRNewswire-FirstCall/ -- IDM Pharma, Inc. (Nasdaq: IDMI) announced today the appointment of Gregory J. Tibbitts to its board of directors, effective April 3, 2008. Mr. Tibbitts is currently the chief financial officer for CryoCor, Inc. (Nasdaq: CRYO), a San Diego-based medical device company and in this role has overseen the transition from a private to public company, as well as from a clinical stage company to the current commercial operation.

"Greg's extensive financial experience will be an asset to IDM Pharma's board of directors," said Timothy P. Walbert, president and chief executive officer of IDM Pharma. "In senior positions at both privately-held and publicly-traded companies, Greg has proven himself to be an executive with strong integrity and outstanding leadership abilities."

During his more than 19 years in the financial and pharmaceutical industries, Mr.Tibbitts has held senior positions in a number of other companies including chief financial officer at Elitra Pharmaceuticals, a privately held drug discovery company. In addition, Mr. Tibbitts served as senior manager at Ernst & Young LLP and division controller at ITT Residential Capital.

Mr. Tibbitts received a bachelor's degree from the University of San Diego and a master's degree from San Diego State University, and is a Certified Public Accountant.

About IDM Pharma

IDM Pharma is focused on the development of innovative cancer products that either destroy cancer cells by activating the immune system or prevent tumor recurrence by triggering a specific adaptive immune response. IDM Pharma is dedicated to maximizing the full therapeutic and commercial potential of each of its innovative products to address the needs of patients and the physicians who treat these patients.

For more information about the company and its products, visit http://www.idm-pharma.com.

Forward-Looking Statements

This press release includes forward-looking statements that reflect management's current views of future events including statements regarding the Company's business activities and Mr. Tibbitts' participation on the Company's Board of Directors. Actual results may differ materially from the forward-looking statements due to a number of important factors, including, but not limited to, whether the Company will be able to provide assurance regarding the quality of the existing L-MTP-PE data and to respond to the remaining issues with regard to the MAA, including verification of data quality and CMC items, to the satisfaction of the CHMP, whether the final opinion of the CHMP will be consistent with the non-binding opinion of the CHMP, whether the European Commission will follow the final opinion of the CHMP once issued, whether the timing for the final opinion of the CHMP and the regulatory decision in Europe will occur as expected by the Company, the possibility that additional data from the Phase 3 clinical trial of L-MTP-PE and other information in any amendment to the NDA for L-MTP-PE submitted by the Company may not provide adequate support for regulatory approval of L-MTP-PE in the United States within the timeframe expected by the Company, if at all, whether the Company will be able to manufacture and commercialize L-MTP-PE even if it is approved by regulatory authorities, and whether the cash resources of the Company will be sufficient to fund operations as planned. These and other risks affecting the Company and its drug development programs, intellectual property rights, personnel and business are more fully discussed in the Company's Annual Report on Form 10-K filed with the SEC for the year ended December 31, 2007 and other periodic reports filed with the SEC. The Company expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.


'/>"/>
SOURCE IDM Pharma Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pharmasset to Present at the Canaccord Adams Hepatitis C Conference on Wednesday, April 9th
2. Pharmacyclics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting
3. Anadys Pharmaceuticals to Present at the CanAccord Adams Hepatitis C Conference
4. Excipients Help Pharma Extend Product Life, Profits
5. PharmAthene Closes Acquisition of Avecia Biodefense Vaccines Business Unit
6. PAREXEL Appoints Leading Central Nervous System Experts to Its Global Clinical Pharmacology Business
7. Abt Associates Clinical Trials Announces Name Change to Abt Bio-Pharma Solutions, Inc.
8. Laureate Pharma Reports Record Growth for 2007
9. DiObex Announces Presentation of Scientific Poster at Annual Meeting of American Society for Clinical Pharmacology and Therapeutics
10. Dragon Pharma announces 2007 full year financial results
11. Transgenomic Opens Pharmacogenomics Laboratory in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... research firm Parks Associates announced today that Tom Kerber ... Annual Meeting , October 11 in Scottsdale, Arizona . ... how smart safety and security products impact the competitive landscape. ... Parks Associates: Smart Home Devices: Main Purchase Driver ... "The residential security market has experienced continued growth, and the ...
(Date:10/9/2017)...  BioTech Holdings announced today identification and patenting ... stem cell therapy prevents limb loss in animal ... that treatment with ProCell resulted in more than ... to standard bone marrow stem cell administration.  Interestingly, ... of therapeutic effect.  ...
(Date:10/9/2017)... Antonio, Texas (PRWEB) , ... ... ... new study published on October 5, 2017, in the medical journal, Epilepsia, ... equivalence with the gold standard, video EEG, in detecting generalized tonic-clonic seizures ...
(Date:10/6/2017)... ... October 06, 2017 , ... The HealthTech Venture Network ... at their fourth annual Conference where founders, investors, innovative practitioners and collaborators are ... pitch competition showcasing early stage digital health and med tech companies. , This ...
Breaking Biology Technology:
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/30/2017)... , March 30, 2017 Trends, opportunities ... (physiological and behavioral), by technology (fingerprint, AFIS, iris recognition, ... recognition, and others), by end use industry (government and ... immigration, financial and banking, and others), and by region ... , Asia Pacific , and ...
(Date:3/27/2017)... 27, 2017  Catholic Health Services (CHS) has ... Society (HIMSS) Analytics for achieving Stage 6 on ... . In addition, CHS previously earned a place ... an electronic medical record (EMR). "HIMSS ... of EMR usage in an outpatient setting.  This ...
Breaking Biology News(10 mins):